<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Phenotypes_acutehepa" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Phenotypes_acutehepa</book-part-id>
      <title-group>
        <title>Acute Hepatitis</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>5</month>
          <year>2019</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Phenotypes_ahn" document-type="chapter">Acute Hepatic Necrosis</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Phenotypes_chol" document-type="chapter">Cholestatic Hepatitis</related-object>
    </book-part-meta>
    <body>
      <p><bold>Description</bold>. The course of illness resembles acute viral hepatitis with insidious onset, a hepatocellular pattern of injury and jaundice. Symptoms (if present) include fatigue, anorexia, nausea and right upper quadrant tenderness. Illness typically lasts 2 to 4 weeks and ultimately resolves, but severe instances can result in acute liver failure and death.</p>
      <p><bold>Latency to Onset</bold>. The time to onset of acute hepatitis is typically 2 to 24 weeks; unlikely after 52 weeks or before 4 days.</p>
      <p><bold>Symptoms</bold>. Typically, an insidious onset of fatigue and nausea, followed by anorexia, abdominal discomfort (liver pain) and then dark urine and jaundice. There may be low grade fever and transient, indefinite rash during the incubation period. Itching is typically absent early in the course, but may arise if jaundice is prolonged.</p>
      <p><bold>Serum Enzyme Elevations</bold>. Peak ALT rising to 800 U/L (~20 times ULN) with accompanying alkaline phosphatase &#x0003c;3 times ULN (&#x0003c;345 U/L). &#x0201c;Probable&#x0201d; cases can have ALT rising to above 400 U/L (~10 times ULN), with alkaline phosphatase &#x0003c;2 times ULN (&#x0003c;230 U/L), particularly later during the course. Serum enzyme may rise for another 5 to 10 days after the medication is stopped and then decrease promptly, typically by 50% within 30 days.</p>
      <p><bold>Drugs</bold>. Typical agents that cause an acute viral hepatitis like illness include isoniazid, pyrazinamide, disulfiram, fenofibrate, ephedra, greater celandine, green tea, and other herbals.</p>
      <p><bold>Differential Diagnosis</bold>. Diagnosis should focus on acute hepatitis A, B, C and E and reactivation of hepatitis B. Acute biliary obstruction can resemble acute hepatitis during the first days after onset. Finally, ischemic hepatitis may superficially resemble acute hepatitis, but the rapid onset and rapid recovery are distinctive.</p>
      <p><bold>Criteria for Definition:</bold> Elements important in diagnosis of acute hepatitis in drug induced liver injury include:</p>
      <list list-type="order">
        <list-item>
          <label>1</label>
          <p>Hepatocellular pattern of serum enzyme elevations with ALT levels rising to above 800 U/L (&#x0003e;20 times ULN) and Alk P levels of less than 3 times ULN (&#x0003c;345 U/L) at the time of peak ALT elevation</p>
        </list-item>
        <list-item>
          <label>2</label>
          <p>Latency of 2 to 24 weeks</p>
        </list-item>
        <list-item>
          <label>3</label>
          <p>Symptoms of fatigue and/or nausea</p>
        </list-item>
        <list-item>
          <label>4</label>
          <p>Bilirubin &#x0003e;2.5 mg/dL</p>
        </list-item>
        <list-item>
          <label>5</label>
          <p>If liver biopsy is obtained, changes of acute hepatocellular necrosis with lobular disarray and lymphocytic infiltration with minimal or no fibrosis.</p>
        </list-item>
      </list>
      <p>A case can be considered &#x0201c;probable&#x0201d; if the peak ALT levels are between 400 to 800 U/L (~10 to 20 times ULN) and accompanying alkaline phosphatase levels are less than 2 times ULN (&#x0003c;230 U/L). A case can be considered &#x0201c;anicteric acute viral hepatitis like&#x0201d; if all criteria are met, but bilirubin is between 1.2 and 2.5 mg/dL and direct bilirubin (if tested) is &#x0003e;0.3 mg/dL. Drug induced acute hepatitis can be accompanied by immunoallergic and autoimmune features and can lead to acute liver failure and possibly cirrhosis. Between 30% and 50% of cases of drug induced liver injury fit this phenotype of being acute viral hepatitis like. This pattern is most likely to result in acute liver failure and the mortality rate of an acute hepatitis like phenotype of drug induced liver injury is at least 10% (so called &#x0201c;Hy&#x02019;s Law&#x0201d;, in reference to Dr. Hyman J. Zimmerman).</p>
      <sec id="Phenotypes_acutehepa.REPRESENTATIVE_CASE">
        <title>REPRESENTATIVE CASES</title>
        <sec id="Phenotypes_acutehepa.Case_1_Acute_hepati">
          <title>Case 1. Acute hepatitis due to isoniazid.(<xref ref-type="bibr" rid="Phenotypes_acutehepa.REF.1">1</xref>)</title>
          <p>A 66 year old Hispanic man developed nausea followed by dark urine and jaundice 6 weeks after starting isoniazid for latent tuberculosis. He had been in good health except for hypertension for which he had been taking enalapril for more than a decade. Because of a positive purified protein derivative (PPD) tuberculin skin test, he was started on a 6 month course of isoniazid [300 mg daily with pyridoxine]. Laboratory tests taken before starting therapy were normal except for a slightly raised total serum bilirubin. He remained asymptomatic until onset of nausea and indigestion during week 6 of therapy. He denied fever or rash. He had not taken any over-the-counter medications, herbals or acetaminophen. He had a history of heavy drinking but had stopped 4 years previously. Physical examination showed jaundice but no signs of chronic liver disease. Laboratory tests showed a total bilirubin of 6.3 mg/dL and marked elevations in ALT, but minimal increase in alkaline phosphatase levels (Table). Tests for hepatitis A, B and C were negative. Serum antinuclear antibody (ANA) was strongly positive (1:20,480), but smooth muscle antibody was negative, and immunoglobulin levels were normal. Liver imaging showed no evidence of biliary obstruction. Liver biopsy was not done. Isoniazid was promptly stopped and he began to improve within days. Enalapril was restarted, but therapy for latent tuberculosis was not pursued. One month later, he was asymptomatic and liver tests had returned to baseline.</p>
          <sec id="Phenotypes_acutehepa.Key_Points">
            <title>Key Points</title>
            <table-wrap id="Phenotypes_acutehepa.Tc" orientation="portrait" position="anchor">
              <table frame="hsides" rules="groups">
                <tbody>
                  <tr>
                    <th id="hd_b_Phenotypes_acutehepa.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Medication:</th>
                    <td headers="hd_b_Phenotypes_acutehepa.Tc_1_1_1_1" valign="top" align="left" rowspan="1" colspan="1">Isoniazid (300 mg daily)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Phenotypes_acutehepa.Tc_1_1_2_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Pattern:</th>
                    <td headers="hd_b_Phenotypes_acutehepa.Tc_1_1_2_1" valign="top" align="left" rowspan="1" colspan="1">Hepatocellular (R=45.9)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Phenotypes_acutehepa.Tc_1_1_3_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Severity:</th>
                    <td headers="hd_b_Phenotypes_acutehepa.Tc_1_1_3_1" valign="top" align="left" rowspan="1" colspan="1">2+ (jaundice, but not hospitalized)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Phenotypes_acutehepa.Tc_1_1_4_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Latency:</th>
                    <td headers="hd_b_Phenotypes_acutehepa.Tc_1_1_4_1" valign="top" align="left" rowspan="1" colspan="1">6 weeks</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Phenotypes_acutehepa.Tc_1_1_5_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Recovery:</th>
                    <td headers="hd_b_Phenotypes_acutehepa.Tc_1_1_5_1" valign="top" align="left" rowspan="1" colspan="1">4 weeks</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Phenotypes_acutehepa.Tc_1_1_6_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Other medications:</th>
                    <td headers="hd_b_Phenotypes_acutehepa.Tc_1_1_6_1" valign="top" align="left" rowspan="1" colspan="1">Enalapril (chronically), pyridoxine</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </sec>
          <sec id="Phenotypes_acutehepa.Laboratory_Values">
            <title>Laboratory Values</title>
            <table-wrap id="Phenotypes_acutehepa.Td" orientation="portrait" position="anchor">
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_Phenotypes_acutehepa.Td_1_1_1_1" valign="top" align="center" scope="col" rowspan="1" colspan="1">Time After<break/>Starting</th>
                    <th id="hd_h_Phenotypes_acutehepa.Td_1_1_1_2" valign="top" align="center" scope="col" rowspan="1" colspan="1">Time After<break/>Stopping</th>
                    <th id="hd_h_Phenotypes_acutehepa.Td_1_1_1_3" valign="top" align="center" scope="col" rowspan="1" colspan="1">ALT<break/>(U/L)</th>
                    <th id="hd_h_Phenotypes_acutehepa.Td_1_1_1_4" valign="top" align="center" scope="col" rowspan="1" colspan="1">Alk P<break/>(U/L)</th>
                    <th id="hd_h_Phenotypes_acutehepa.Td_1_1_1_5" valign="top" align="center" scope="col" rowspan="1" colspan="1">Bilirubin (mg/dL)</th>
                    <th id="hd_h_Phenotypes_acutehepa.Td_1_1_1_6" valign="top" align="center" scope="col" rowspan="1" colspan="1">Other</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Pre</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">29</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">71</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">1.7</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">0</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_3 hd_h_Phenotypes_acutehepa.Td_1_1_1_4 hd_h_Phenotypes_acutehepa.Td_1_1_1_5 hd_h_Phenotypes_acutehepa.Td_1_1_1_6" colspan="4" valign="top" align="center" rowspan="1">Isoniazid (300 mg daily) started</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">6 weeks</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">0</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">2326</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">114</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">6.3</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_6" valign="top" align="center" rowspan="1" colspan="1">Isoniazid stopped</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">1 day</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">2486</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">137</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">9.0</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_6" valign="top" align="center" rowspan="1" colspan="1">INR=1.2</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">4 days</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">1836</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">113</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">9.5</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">7 weeks</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">1 week</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">773</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">104</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">6.1</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">2 months</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">2 weeks</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">199</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">80</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">2.6</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">3 months</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">5 weeks</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">32</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">64</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">1.3</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_1 hd_h_Phenotypes_acutehepa.Td_1_1_1_2" colspan="2" valign="top" align="center" scope="row" rowspan="1">
                      <bold>Normal Values</bold>
                    </td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">
                      <bold>&#x0003c;56</bold>
                    </td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">
                      <bold>&#x0003c;130</bold>
                    </td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">
                      <bold>&#x0003c;1.2</bold>
                    </td>
                    <td headers="hd_h_Phenotypes_acutehepa.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </sec>
          <sec id="Phenotypes_acutehepa.Comment">
            <title>Comment</title>
            <p>Isoniazid hepatotoxicity typically presents like acute viral hepatitis with a prodrome of fatigue, nausea, poor appetite and right upper quadrant pain, followed by dark urine and jaundice, arising 4 to 24 weeks after starting therapy. Symptoms and signs may worsen for a few days after stopping isoniazid, but then usually improve rapidly. Immunoallergic features are unusual and, if present, are mild. Isoniazid therapy can induce ANA reactivity, but autoantibodies titers are usually low (making this case somewhat atypical) and not associated with other features that would suggest autoimmune hepatitis. Age above 35 years is the single major risk factor for isoniazid hepatitis. Alcohol use may also be a risk factor, but it is not clear whether the risk is related to concurrent use or with an alcohol history (probably the former). Treatment of latent tuberculosis in persons over the age of 35 should be done with caution. Patients should be informed of the risk of liver injury and warned of the signs and symptoms of liver injury. Routine biochemical monitoring is prudent if there is preexisting liver disease or perceived increased risk for liver injury. The mortality rate of isoniazid hepatitis with jaundice is at least 10%.</p>
          </sec>
        </sec>
        <sec id="Phenotypes_acutehepa.Case_2_Acute_hepati">
          <title>Case 2. Acute hepatitis due to fenofibrate therapy.(<xref ref-type="bibr" rid="Phenotypes_acutehepa.REF.2">2</xref>)</title>
          <p>A 74 year old woman developed jaundice having been on oral therapy with fenofibrate (200 mg daily) for two years. She was not taking other medications and had no history of liver disease, alcohol use, or exposures to hepatitis. On hospital admission, physical examination revealed jaundice but no fever or rash. Laboratory findings included marked elevations in serum aminotransferase levels (Table) and bilirubin of 4.7 mg/dL. Tests for hepatitis A and B were negative, as were autoantibodies. Abdominal ultrasound and endoscopic retrograde cholangiopancreatography showed no evidence of biliary obstruction. During the first week in the hospital, serum bilirubin rose to 13.3 mg/dL and prothrombin time decreased to 46% of normal. At this point, fenofibrate was stopped and she then began to improve, with rapid regression of jaundice, allowing her to be discharged after 25 days in the hospital. In follow up over the next year, her abnormal liver tests returned to normal.</p>
          <sec id="Phenotypes_acutehepa.Key_Points_1">
            <title>Key Points</title>
            <table-wrap id="Phenotypes_acutehepa.Te" orientation="portrait" position="anchor">
              <table frame="hsides" rules="groups">
                <tbody>
                  <tr>
                    <th id="hd_b_Phenotypes_acutehepa.Te_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Medication:</th>
                    <td headers="hd_b_Phenotypes_acutehepa.Te_1_1_1_1" valign="top" align="left" rowspan="1" colspan="1">Fenofibrate (200 mg daily)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Phenotypes_acutehepa.Te_1_1_2_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Pattern:</th>
                    <td headers="hd_b_Phenotypes_acutehepa.Te_1_1_2_1" valign="top" align="left" rowspan="1" colspan="1">Hepatocellular (R=12)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Phenotypes_acutehepa.Te_1_1_3_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Severity:</th>
                    <td headers="hd_b_Phenotypes_acutehepa.Te_1_1_3_1" valign="top" align="left" rowspan="1" colspan="1">4+ (jaundice, hospitalization, prolongation of prothrombin time)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Phenotypes_acutehepa.Te_1_1_4_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Latency:</th>
                    <td headers="hd_b_Phenotypes_acutehepa.Te_1_1_4_1" valign="top" align="left" rowspan="1" colspan="1">2 years</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Phenotypes_acutehepa.Te_1_1_5_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Recovery:</th>
                    <td headers="hd_b_Phenotypes_acutehepa.Te_1_1_5_1" valign="top" align="left" rowspan="1" colspan="1">2 months</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Phenotypes_acutehepa.Te_1_1_6_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Other medications:</th>
                    <td headers="hd_b_Phenotypes_acutehepa.Te_1_1_6_1" valign="top" align="left" rowspan="1" colspan="1">None mentioned</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </sec>
          <sec id="Phenotypes_acutehepa.Laboratory_Values_1">
            <title>Laboratory Values</title>
            <table-wrap id="Phenotypes_acutehepa.Tf" orientation="portrait" position="anchor">
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_Phenotypes_acutehepa.Tf_1_1_1_1" valign="top" align="center" scope="col" rowspan="1" colspan="1">Time After<break/>Starting</th>
                    <th id="hd_h_Phenotypes_acutehepa.Tf_1_1_1_2" valign="top" align="center" scope="col" rowspan="1" colspan="1">Time After<break/>Stopping</th>
                    <th id="hd_h_Phenotypes_acutehepa.Tf_1_1_1_3" valign="top" align="center" scope="col" rowspan="1" colspan="1">AST<break/>(U/L)</th>
                    <th id="hd_h_Phenotypes_acutehepa.Tf_1_1_1_4" valign="top" align="center" scope="col" rowspan="1" colspan="1">GGT<break/>(U/L)</th>
                    <th id="hd_h_Phenotypes_acutehepa.Tf_1_1_1_5" valign="top" align="center" scope="col" rowspan="1" colspan="1">Bilirubin (mg/dL)</th>
                    <th id="hd_h_Phenotypes_acutehepa.Tf_1_1_1_6" valign="top" align="center" scope="col" rowspan="1" colspan="1">Other</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_3 hd_h_Phenotypes_acutehepa.Tf_1_1_1_4 hd_h_Phenotypes_acutehepa.Tf_1_1_1_5 hd_h_Phenotypes_acutehepa.Tf_1_1_1_6" colspan="4" valign="top" align="center" rowspan="1">Started on fenofibrate for hyperlipidemia</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">2 years</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">0</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">1430</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">142</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">4.6</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_6" valign="top" align="center" rowspan="1" colspan="1">Alk P=315 (6 fold elevated)</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">+7 days</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">0</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">900</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">160</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">12.5</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">+10 days</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">0</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">800</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">160</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">13.3</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_6" valign="top" align="center" rowspan="1" colspan="1">Fenofibrate stopped</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">4 days</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">540</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">200</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">12.8</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">8 days</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">400</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">11.3</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">12 days</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">440</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">8.8</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">1 month</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">23</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">4.3</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">2 months</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">30</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">0.7</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_1 hd_h_Phenotypes_acutehepa.Tf_1_1_1_2" colspan="2" valign="top" align="center" scope="row" rowspan="1">
                      <bold>Normal Values</bold>
                    </td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">
                      <bold>&#x0003c;20</bold>
                    </td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">
                      <bold>&#x0003c;25</bold>
                    </td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">
                      <bold>&#x0003c;1.2</bold>
                    </td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tf_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </sec>
          <sec id="Phenotypes_acutehepa.Comment_1">
            <title>Comment</title>
            <p>This patient developed a fairly severe, acute hepatitis while on long term fenofibrate therapy. The long latency to onset of injury was unusual, and initially her physicians did not think that the fenofibrate was the cause. Because of worsening jaundice over the next 10 days, however, the role of fenofibrate was reconsidered and it was stopped, whereupon she began to improve. The hepatic injury was severe and associated with prolongation of prothrombin time and worsening liver function tests. Liver biopsy was not performed and tests for hepatitis C were not available. Nevertheless, fenofibrate is a known cause of an acute hepatitis like syndrome and was probably the cause of this acute injury.</p>
          </sec>
        </sec>
        <sec id="Phenotypes_acutehepa.Case_3_Acute_hepati">
          <title>Case 3. Acute hepatitis after using weight loss supplement.(<xref ref-type="bibr" rid="Phenotypes_acutehepa.REF.3">3</xref>)</title>
          <p>A 37 year old woman developed nausea, abdominal pain and jaundice 4 months after starting a weight loss supplement called The Right Approach Complex (Pharmanex, Provo, Utah), the major component of which was green tea extract (Camellia sinesis). She denied history of liver disease, alcohol use, and risk factors for viral hepatitis. On examination, she was jaundiced but had no fever or rash. Laboratory tests showed a serum bilirubin of 11.7 mg/dL and marked elevations in serum aminotransferase levels (~20 times ULN) with minimal increases in alkaline phosphatase (Table). Tests for hepatitis A, B and C were negative as were autoantibodies, except for antinuclear antibody which was weakly positive (1:40, speckled pattern). Liver biopsy revealed marked interface necrosis and inflammation and mild lobular inflammation. Cholecystectomy and intraoperative cholangiography were performed. The patient began to improve rapidly and was discharged after two weeks in the hospital. One month later, liver tests had improved significantly. One year later, she was again admitted with a one week history of abdominal pain and jaundice. She admitted to resuming The Right Approach Complex one month earlier, but stopped taking it one week before presentation when she developed dysphagia. On admission, she was jaundiced. She again improved rapidly and six months later all liver tests were normal.</p>
          <sec id="Phenotypes_acutehepa.Key_Points_2">
            <title>Key Points</title>
            <table-wrap id="Phenotypes_acutehepa.Tg" orientation="portrait" position="anchor">
              <table frame="hsides" rules="groups">
                <tbody>
                  <tr>
                    <th id="hd_b_Phenotypes_acutehepa.Tg_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Medication:</th>
                    <td headers="hd_b_Phenotypes_acutehepa.Tg_1_1_1_1" valign="top" align="left" rowspan="1" colspan="1">The Right Choice (383.3 mg Camellia sinensis extract per 3 capsules)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Phenotypes_acutehepa.Tg_1_1_2_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Pattern:</th>
                    <td headers="hd_b_Phenotypes_acutehepa.Tg_1_1_2_1" valign="top" align="left" rowspan="1" colspan="1">Hepatocellular</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Phenotypes_acutehepa.Tg_1_1_3_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Severity:</th>
                    <td headers="hd_b_Phenotypes_acutehepa.Tg_1_1_3_1" valign="top" align="left" rowspan="1" colspan="1">3+</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Phenotypes_acutehepa.Tg_1_1_4_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Latency:</th>
                    <td headers="hd_b_Phenotypes_acutehepa.Tg_1_1_4_1" valign="top" align="left" rowspan="1" colspan="1">4 months initially, 1 month on reexposure</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Phenotypes_acutehepa.Tg_1_1_5_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Recovery:</th>
                    <td headers="hd_b_Phenotypes_acutehepa.Tg_1_1_5_1" valign="top" align="left" rowspan="1" colspan="1">1 month</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Phenotypes_acutehepa.Tg_1_1_6_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Other medications:</th>
                    <td headers="hd_b_Phenotypes_acutehepa.Tg_1_1_6_1" valign="top" align="left" rowspan="1" colspan="1">None mentioned</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </sec>
          <sec id="Phenotypes_acutehepa.Laboratory_Values_2">
            <title>Laboratory Values</title>
            <table-wrap id="Phenotypes_acutehepa.Th" orientation="portrait" position="anchor">
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_Phenotypes_acutehepa.Th_1_1_1_1" valign="top" align="center" scope="col" rowspan="1" colspan="1">Time After<break/>Starting</th>
                    <th id="hd_h_Phenotypes_acutehepa.Th_1_1_1_2" valign="top" align="center" scope="col" rowspan="1" colspan="1">Time After<break/>Stopping</th>
                    <th id="hd_h_Phenotypes_acutehepa.Th_1_1_1_3" valign="top" align="center" scope="col" rowspan="1" colspan="1">ALT<break/>(U/L)</th>
                    <th id="hd_h_Phenotypes_acutehepa.Th_1_1_1_4" valign="top" align="center" scope="col" rowspan="1" colspan="1">AST<break/>(U/L)</th>
                    <th id="hd_h_Phenotypes_acutehepa.Th_1_1_1_5" valign="top" align="center" scope="col" rowspan="1" colspan="1">Alk P<break/>(U/L)</th>
                    <th id="hd_h_Phenotypes_acutehepa.Th_1_1_1_6" valign="top" align="center" scope="col" rowspan="1" colspan="1">Bilirubin (mg/dL)</th>
                    <th id="hd_h_Phenotypes_acutehepa.Th_1_1_1_7" valign="top" align="center" scope="col" rowspan="1" colspan="1">Other</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_3 hd_h_Phenotypes_acutehepa.Th_1_1_1_4 hd_h_Phenotypes_acutehepa.Th_1_1_1_5 hd_h_Phenotypes_acutehepa.Th_1_1_1_6 hd_h_Phenotypes_acutehepa.Th_1_1_1_7" colspan="5" valign="top" align="center" rowspan="1">Started The Right Approach (~1 gram of green tea extract daily)</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">16 weeks</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">0</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">1788</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">1783</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">238</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_6" valign="top" align="center" rowspan="1" colspan="1">11.7</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_7" valign="top" align="center" rowspan="1" colspan="1">Liver biopsy, interface necrosis and lobular inflammation</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">18 weeks</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">2 weeks</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">92</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">79</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">-</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_6" valign="top" align="center" rowspan="1" colspan="1">1.9</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_7" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_3 hd_h_Phenotypes_acutehepa.Th_1_1_1_4 hd_h_Phenotypes_acutehepa.Th_1_1_1_5 hd_h_Phenotypes_acutehepa.Th_1_1_1_6 hd_h_Phenotypes_acutehepa.Th_1_1_1_7" colspan="5" valign="top" align="center" rowspan="1">Restarted The Right Approach 1 year later</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">4 weeks</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">0</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">1131</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">977</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">165</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_6" valign="top" align="center" rowspan="1" colspan="1">11.7</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_7" valign="top" align="center" rowspan="1" colspan="1">INR: 1.3</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">5 weeks</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">1 week</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">877</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">816</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">165</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_6" valign="top" align="center" rowspan="1" colspan="1">2.9</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_7" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">2 months</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">5 weeks</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">69</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">80</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">-</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_6" valign="top" align="center" rowspan="1" colspan="1">1.2</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_7" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">7 months</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">6 months</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">25</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">27</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_5" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_6" valign="top" align="center" rowspan="1" colspan="1">1.0</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_7" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_1 hd_h_Phenotypes_acutehepa.Th_1_1_1_2" colspan="2" valign="top" align="center" scope="row" rowspan="1">
                      <bold>Normal Values</bold>
                    </td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">
                      <bold>&#x0003c;35</bold>
                    </td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">
                      <bold>&#x0003c;35</bold>
                    </td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">
                      <bold>&#x0003c;130</bold>
                    </td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_6" valign="top" align="center" rowspan="1" colspan="1">
                      <bold>&#x0003c;1.2</bold>
                    </td>
                    <td headers="hd_h_Phenotypes_acutehepa.Th_1_1_1_7" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </sec>
          <sec id="Phenotypes_acutehepa.Comment_2">
            <title>Comment</title>
            <p>This case demonstrates the typical acute viral hepatitis like presentation of green tea hepatotoxicity with jaundice, accompanied by marked elevations in serum aminotransferase levels and minimal increases in alkaline phosphatase. Recurrence with a similar pattern of liver injury upon reexposure to the same product provided clear evidence of a causal association. Green tea extract was the major ingredient of the supplement and its other components have not been reported to cause liver injury (calcium, chromium, magnolia extract, epimedium extract, banaba leaf extract, &#x003b2;-sitosterol and vanadium). The hepatotoxicity of herbal products has become an increasing problem with the increasing use of these agents. Interestingly, the liver injury is usually hepatocellular and resembles acute viral hepatitis.</p>
          </sec>
        </sec>
        <sec id="Phenotypes_acutehepa.Case_4_Acute_hepati">
          <title>Case 4. Acute hepatitis and jaundice after disulfiram in an alcoholic patient with chronic hepatitis C.(<xref ref-type="bibr" rid="Phenotypes_acutehepa.REF.4">4</xref>)</title>
          <p>[DILIN Case #105-0050]</p>
          <p>A 42 year old male with chronic hepatitis C was started on disulfiram (Anabuse) for chronic alcohol abuse and lisinopril for hypertension. A few days later he developed diarrhea and stopped lisinopril. One to two weeks later he developed fatigue, nausea, vomiting and poor appetite, but he continued taking disulfiram until he developed jaundice 30 days after starting. He sought medical attention 2 days later and was hospitalized for evaluation. He had a history of type 2 diabetes for which he had been taking metformin for several years. He claimed to have had no alcohol intake since starting Antabuse and admission serum alcohol level was negative. His chronic hepatitis C (genotype 1, HCV RNA 32,300 IU/mL) was considered mild and had never been treated. Physical examination showed no fever, rash or signs of chronic liver disease. He was mildly jaundiced. Laboratory tests revealed a total serum bilirubin of 5.9 mg/dL with marked elevations in ALT (1715 U/L) and AST (919 U/L), but normal alkaline phosphatase levels (95 U/L). Tests for hepatitis A and B were negative as were autoantibodies. An abdominal ultrasound showed a normal liver texture and no evidence of biliary obstruction which was confirmed by magnetic resonance cholangiography. Over the next few days, he began to improve and serum bilirubin was normal one week later. In follow up, his symptoms resolved and serum ALT levels fell to baseline values. Importantly, HCV RNA was undetectable during the acute injury, but reappeared once it had resolved. One year after this episode, he again had detectable serum HCV RNA and ALT levels were mildly elevated. He was subsequently treated with a course of peginterferon and ribavirin and achieved a sustained virological response. In recent follow up, he has had normal serum aminotransferase levels and no detectable HCV RNA.</p>
          <sec id="Phenotypes_acutehepa.Key_Points_3">
            <title>Key Points</title>
            <table-wrap id="Phenotypes_acutehepa.Ti" orientation="portrait" position="anchor">
              <table frame="hsides" rules="groups">
                <tbody>
                  <tr>
                    <th id="hd_b_Phenotypes_acutehepa.Ti_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Medication:</th>
                    <td headers="hd_b_Phenotypes_acutehepa.Ti_1_1_1_1" valign="top" align="left" rowspan="1" colspan="1">Disulfiram (100 mg daily)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Phenotypes_acutehepa.Ti_1_1_2_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Pattern:</th>
                    <td headers="hd_b_Phenotypes_acutehepa.Ti_1_1_2_1" valign="top" align="left" rowspan="1" colspan="1">Hepatocellular (R=41)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Phenotypes_acutehepa.Ti_1_1_3_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Severity:</th>
                    <td headers="hd_b_Phenotypes_acutehepa.Ti_1_1_3_1" valign="top" align="left" rowspan="1" colspan="1">3+ (jaundice, hospitalization)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Phenotypes_acutehepa.Ti_1_1_4_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Latency:</th>
                    <td headers="hd_b_Phenotypes_acutehepa.Ti_1_1_4_1" valign="top" align="left" rowspan="1" colspan="1">32 days</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Phenotypes_acutehepa.Ti_1_1_5_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Recovery:</th>
                    <td headers="hd_b_Phenotypes_acutehepa.Ti_1_1_5_1" valign="top" align="left" rowspan="1" colspan="1">Uncertain timing</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Phenotypes_acutehepa.Ti_1_1_6_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Other medications:</th>
                    <td headers="hd_b_Phenotypes_acutehepa.Ti_1_1_6_1" valign="top" align="left" rowspan="1" colspan="1">Metformin (3 years), lisinopril (for 1 week, 3 weeks before presentation)</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </sec>
          <sec id="Phenotypes_acutehepa.Laboratory_Values_3">
            <title>Laboratory Values</title>
            <table-wrap id="Phenotypes_acutehepa.Tj" orientation="portrait" position="anchor">
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_Phenotypes_acutehepa.Tj_1_1_1_1" valign="top" align="center" scope="col" rowspan="1" colspan="1">Time After<break/>Starting</th>
                    <th id="hd_h_Phenotypes_acutehepa.Tj_1_1_1_2" valign="top" align="center" scope="col" rowspan="1" colspan="1">Time After<break/>Stopping</th>
                    <th id="hd_h_Phenotypes_acutehepa.Tj_1_1_1_3" valign="top" align="center" scope="col" rowspan="1" colspan="1">ALT<break/>(U/L)</th>
                    <th id="hd_h_Phenotypes_acutehepa.Tj_1_1_1_4" valign="top" align="center" scope="col" rowspan="1" colspan="1">Alk P<break/>(U/L)</th>
                    <th id="hd_h_Phenotypes_acutehepa.Tj_1_1_1_5" valign="top" align="center" scope="col" rowspan="1" colspan="1">Bilirubin (mg/dL)</th>
                    <th id="hd_h_Phenotypes_acutehepa.Tj_1_1_1_6" valign="top" align="center" scope="col" rowspan="1" colspan="1">Other</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Pre</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">Pre</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">49</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">52</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">0.9</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">5 days</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">0</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_3 hd_h_Phenotypes_acutehepa.Tj_1_1_1_4 hd_h_Phenotypes_acutehepa.Tj_1_1_1_5 hd_h_Phenotypes_acutehepa.Tj_1_1_1_6" colspan="4" valign="top" align="center" rowspan="1">Fatigue, nausea, anorexia</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">30 days</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">0</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_3 hd_h_Phenotypes_acutehepa.Tj_1_1_1_4 hd_h_Phenotypes_acutehepa.Tj_1_1_1_5 hd_h_Phenotypes_acutehepa.Tj_1_1_1_6" colspan="4" valign="top" align="center" rowspan="1">Jaundice, disulfiram stopped</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">32 days</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">2 days</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">1715</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">95</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">5.9</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">33 days</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">3 days</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">1305</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">93</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">5.1</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_6" valign="top" align="center" rowspan="1" colspan="1">HCV RNA negative</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">35 days</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">5 days</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">1238</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">137</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">5.6</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">40 days</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">10 days</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">562</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">109</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">2.0</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">41 days</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">11 days</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">406</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">98</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">1.6</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">1 year</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">1 year</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">59</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">83</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">0.3</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_6" valign="top" align="center" rowspan="1" colspan="1">HCV RNA 385,000 IU/mL</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_3 hd_h_Phenotypes_acutehepa.Tj_1_1_1_4 hd_h_Phenotypes_acutehepa.Tj_1_1_1_5 hd_h_Phenotypes_acutehepa.Tj_1_1_1_6" colspan="4" valign="top" align="center" rowspan="1">Treated with peginterferon and ribavirin with sustained virological response</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">4 years</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">4 years</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">26</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">97</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">0.8</td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_6" valign="top" align="center" rowspan="1" colspan="1">HCV RNA negative</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_1 hd_h_Phenotypes_acutehepa.Tj_1_1_1_2" colspan="2" valign="top" align="center" scope="row" rowspan="1">
                      <bold>Normal Values</bold>
                    </td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">
                      <bold>&#x0003c;42</bold>
                    </td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">
                      <bold>&#x0003c;115</bold>
                    </td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">
                      <bold>&#x0003c;1.2</bold>
                    </td>
                    <td headers="hd_h_Phenotypes_acutehepa.Tj_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </sec>
          <sec id="Phenotypes_acutehepa.Comment_3">
            <title>Comment</title>
            <p>Despite having chronic hepatitis C and alcoholism, the acute injury that began within a month of starting disulfiram was clearly due to this medication rather than HCV or alcoholic hepatic injury. Disulfiram typically causes an acute hepatitis like syndrome 2 to 12 weeks after starting the medication that can be severe and lead to acute liver failure or need for liver transplantation. Alcoholic liver injury can cause jaundice and symptoms, but rarely causes serum aminotransferase elevations above 5 to 8 times the upper limit of normal and AST values are usually higher than ALT values. Chronic hepatitis C can be associated with flares of disease activity, but these are rarely associated with symptoms or jaundice unless cirrhosis is present. Importantly, HCV RNA levels usually increase or are stable during flares of hepatitis C but fall markedly (and may be below the level of detection) during acute superimposed forms of liver injury.</p>
          </sec>
        </sec>
      </sec>
      <sec id="Phenotypes_acutehepa.CITED_REFERENCES">
        <title>CITED REFERENCES</title>
        <ref-list id="Phenotypes_acutehepa.CITED_REFERENCES.reflist0">
          <ref id="Phenotypes_acutehepa.REF.1">
            <label>1</label>
            <mixed-citation publication-type="other">DILIN Case #102-0056.</mixed-citation>
          </ref>
          <ref id="Phenotypes_acutehepa.REF.2">
            <label>2</label>
            <mixed-citation publication-type="other">Rigal J, Furet Y, Autret E, Breteau M. [Severe mixed hepatitis caused by fenofibrate? A review of the literature apropos of a case]. Rev Med Interne 1989; 10: 65-7. 2655052</mixed-citation>
          </ref>
          <ref id="Phenotypes_acutehepa.REF.3">
            <label>3</label>
            <mixed-citation publication-type="other">Bonkovsky HL. Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann Intern Med 2006; 144: 68-71. 16389263</mixed-citation>
          </ref>
          <ref id="Phenotypes_acutehepa.REF.4">
            <label>4</label>
            <mixed-citation publication-type="other">DILIN Case #105-0050.</mixed-citation>
          </ref>
        </ref-list>
      </sec>
      <sec id="Phenotypes_acutehepa.HEPATIC_HISTOLOGY_O">
        <title>HEPATIC HISTOLOGY OF ACUTE HEPATITIS</title>
        <p>Histologically, acute hepatitis is charactized by diffuse parenchymal injury. The hepatocytes may show cell swelling or apoptosis and in most cases there are numerous small foci of lobular inflammation. The inflammation may consist of any combination of lymphocytes, macrophages and plasma cells. Portal inflammation may be present, but is not necessary. Lobular disarray results when there is disruption of the sinusoidal architecture by cell injury and inflammation. Hepatocyte rosettes and mitotic figures may be seen as evidence of liver regeneration. Cholestasis in the form of visible bile in canaliculi and hepatocyte cytoplasm is sometimes seen in acinar zone 3. When the cholestasis is prominent compared to the inflammation, the case should be classified as cholestatic hepatitis rather than acute hepatitis. In severe cases there may be multiacinar or bridging necrosis and these changes can lead to submassive or massive hepatic necrosis and hepatic failure. Mild cases may show only foci of lobular inflammation or hepatocyte apoptosis. The presence of significant fibrosis (more than portal fibrotic expansion) should suggest acute hepatitis superimposed on chronic hepatitis. Cases that are in a resolving phase will often show only clusters of pigmented macrophages in the parenchyma and portal areas.</p>
      </sec>
      <sec id="Phenotypes_acutehepa.Histologic_Images">
        <title>Histologic Images</title>
        <p>Photomicrographs by</p>
        <p>David E. Kleiner, MD, PhD</p>
        <p>Laboratory of Pathology</p>
        <p>National Cancer Institute</p>
        <p>(<inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="Livertox.AcuteHepatitis.pdf" content-type="local-data">See high resolution images</inline-supplementary-material>)</p>
        <fig id="Phenotypes_acutehepa.Fa" orientation="portrait" position="anchor">
          <caption>
            <p>Case A. Acute Hepatitis Ascribed to Green Tea Containing Herbal Product</p>
            <p>Histologic Features to Note:</p>
            <p>Acute hepatitis with zone 3 necrosis. There is a loss of the hepatocytes around the hepatic vein (V), but unlike cases of acute hepatic necrosis, there is abundant lymphocytic inflammation within and around the area of necrosis.</p>
            <p>(<inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="Livertox_AcuteHepatitis_0002.pdf" content-type="local-data">See high resolution image</inline-supplementary-material>)</p>
          </caption>
          <long-desc>Case A. Acute Hepatitis Ascribed to Green Tea Containing Herbal Product. Acute hepatitis with zone 3 necrosis.</long-desc>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Phenotypes_acutehepa-Image001" position="anchor" orientation="portrait"/>
        </fig>
        <fig id="Phenotypes_acutehepa.Fb" orientation="portrait" position="anchor">
          <caption>
            <p>Case A. Acute Hepatitis Ascribed to Green Tea (continued)</p>
            <p>Histologic Features to Note:</p>
            <p>There is a loss of hepatocytes between the portal area (P) and the vein (V), a change known as bridging necrosis.</p>
            <p>(<inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="Livertox_AcuteHepatitis_0003.pdf" content-type="local-data">See high resolution image</inline-supplementary-material>)</p>
          </caption>
          <long-desc>Case A. Acute Hepatitis Ascribed to Green Tea (continued). There is a loss of hepatocytes between the portal area (P) and the vein (V), a change known as bridging necrosis.</long-desc>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Phenotypes_acutehepa-Image002" position="anchor" orientation="portrait"/>
        </fig>
        <fig id="Phenotypes_acutehepa.Fc" orientation="portrait" position="anchor">
          <caption>
            <p>Case B. Acute Hepatitis Probably Due to Azithromycin</p>
            <p>Histologic Features to Note:</p>
            <p>There are apoptotic hepatocytes (arrows) and many small foci of lymphocytic inflammation associated with loss of sinusoidal architecture (lobular disarray).</p>
            <p>(<inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="Livertox_AcuteHepatitis_0004.pdf" content-type="local-data">See high resolution image</inline-supplementary-material>)</p>
          </caption>
          <long-desc>Case B. Acute Hepatitis Probably Due to Azithromycin. There are apoptotic hepatocytes (arrows) and many small foci of lymphocytic inflammation associated with loss of sinusoidal architecture (lobular disarray).</long-desc>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Phenotypes_acutehepa-Image003" position="anchor" orientation="portrait"/>
        </fig>
        <fig id="Phenotypes_acutehepa.Fd" orientation="portrait" position="anchor">
          <caption>
            <p>Case C. Acute Hepatitis Due to Etanercept</p>
            <p>Histologic Features to Note:</p>
            <p>There is lobular disarray with hepatocyte regeneration. The inflammation is not marked, but scattered foci of lymphocytic infiltration are present.</p>
            <p>(<inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="Livertox_AcuteHepatitis_0005.pdf" content-type="local-data">See high resolution image</inline-supplementary-material>)</p>
          </caption>
          <long-desc>Case C. Acute Hepatitis Due to Etanercept. There is lobular disarray with hepatocyte regeneration.</long-desc>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Phenotypes_acutehepa-Image004" position="anchor" orientation="portrait"/>
        </fig>
        <fig id="Phenotypes_acutehepa.Fe" orientation="portrait" position="anchor">
          <caption>
            <p>Case C. Acute Hepatitis Due to Etanercept (continued)</p>
            <p>Histologic Features to Note:</p>
            <p>At higher magnification there are many hepatocyte rosettes (fat arrows) and a few apoptotic hepatocytes (thin arrows).</p>
            <p>(<inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="Livertox_AcuteHepatitis_0006.pdf" content-type="local-data">See high resolution image</inline-supplementary-material>)</p>
          </caption>
          <long-desc>Case C. Acute Hepatitis Due to Etanercept (continued). At higher magnification there are many hepatocyte rosettes (fat arrows) and a few apoptotic hepatocytes (thin arrows).</long-desc>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Phenotypes_acutehepa-Image005" position="anchor" orientation="portrait"/>
        </fig>
        <fig id="Phenotypes_acutehepa.Ff" orientation="portrait" position="anchor">
          <caption>
            <p>Case D. Acute Hepatitis Due to Isoniazid</p>
            <p>Histologic Features to Note:</p>
            <p>There is marked inflammation with hepatocyte rosette formation and lobular disarray. There is also an area of confluent necrosis (N) with pigmented macrophages.</p>
            <p>(<inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="Livertox_AcuteHepatitis_0007.pdf" content-type="local-data">See high resolution image</inline-supplementary-material>)</p>
          </caption>
          <long-desc>Case D. Acute Hepatitis Due to Isoniazid. There is marked inflammation with hepatocyte rosette formation and lobular disarray.</long-desc>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Phenotypes_acutehepa-Image006" position="anchor" orientation="portrait"/>
        </fig>
        <fig id="Phenotypes_acutehepa.Fg" orientation="portrait" position="anchor">
          <caption>
            <p>Case D. Acute Hepatitis Due to Isoniazid (continued)</p>
            <p>Histologic Features to Note:</p>
            <p>This photo shows a portal area on the left and the hepatocellular parenchyma on the right. The hepatocyte interface is obscured by inflammation.</p>
            <p>(<inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="Livertox_AcuteHepatitis_0008.pdf" content-type="local-data">See high resolution image</inline-supplementary-material>)</p>
          </caption>
          <long-desc>Case D. Acute Hepatitis Due to Isoniazid (continued). This photo shows a portal area on the left and the hepatocellular parenchyma on the right.</long-desc>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Phenotypes_acutehepa-Image007" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
